Alltrna
The world’s first transfer RNA (tRNA) platform company. We are unlocking the vast therapeutic potential within #tRNA.
The world’s first transfer RNA (tRNA) platform company. We are unlocking the vast therapeutic potential within #tRNA.
Alltrna is a pioneering transfer RNA (tRNA) platform company, founded in 2018 at Flagship Labs. The company's mission is to unlock tRNA biology and revolutionize tRNA therapeutics to regulate the protein universe and address various diseases. Alltrna's innovative platform, combining internal expertise and proprietary machine learning tools, aims to unlock the entire tRNA biology space. In August 2023, the company secured a significant $109.00M Series B investment from Flagship Pioneering. This substantial investment showcases the confidence and support of reputable investors in Alltrna's groundbreaking approach. With its pioneering vision and strong financial backing, Alltrna is poised to make a significant impact in the Biotechnology and Health Care industries, potentially transforming the landscape of therapeutic interventions.
| Funding Stage | Amount | No. Investors | Investors | Date |
|---|---|---|---|---|
| Series B | $109.00M | 1 |
|
09 Aug 2023 |
| Venture Round | $50.00M | 1 |
|
09 Nov 2021 |
No recent news or press coverage available for Alltrna.
We care about your data, and we'd love to use cookies make your experience better.
